Epitomics Signs Agreement with Bayer for Antibody Technology
Burlingame, CA - May 26, 2011
Epitomics, Inc. announced today that they have signed a service agreement with Bayer Schering Pharma AG, Germany (Bayer HealthCare). Epitomics will use their proprietary rabbit monoclonal antibody technology to produce antibodies for Bayer HealthCare’s drug target identification and validation.
“Epitomics has had a long-standing experience with Bayer HealthCare. This new agreement is a major expansion of our collaboration and confirms the success of our premium technology platform” said Guo-Liang Yu, PhD, CEO of Epitomics, Inc.
“Our recent experience with the Epitomics rabbit antibody technology has been impressive and we are very pleased to be expanding our collaboration with Epitomics ” said Clive R.Wood, Ph.D., Senior VP and Head of Global Biologics, Bayer HealthCare.
About Epitomics, Inc.
Epitomics, Inc, is a biotechnology company dedicated to developing breakthrough monoclonal antibody technology for research and diagnostic applications. The Company's core technology is its unique and proprietary RabMAb®(Rabbit Monoclonal Antibody) technology which produces antibodies with superior binding affinity and bioactivity in a wide variety of biological assays. Epitomics has also developed a proprietary method for humanizing RabMAbs called Mutation Lineage Guided (MLG) humanization. Epitomics, Inc. is headquartered in Burlingame, California, and operates a wholly owned subsidiary in Hangzhou, the People's Republic of China.